Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 11:59:57 18/07/2024 BST			5-day change	1st Jan Change
8.9 ^SEK	-2.20%		-1.11%	-3.68%

05-10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Initiator Pharma Seeks IPO

January 17, 2017 at 05:00 am

Initiator Pharma A/S Said On January 16, 2017, received notice of approval for listing at AktieTorget. March 16, 2017 is the projected dated for the first day of trading.

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Initiator Pharma Issues New Shares for Debt Conversion	02-21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	01-08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	06/10/23	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	19/09/23	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	09/08/23	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	09/08/23	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	18/07/23	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	05/07/23	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	29/06/23	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	05/06/23	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	25/05/23	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	02/05/23	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	06/03/23	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	20/12/22	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	04/11/22	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/11/22	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	04/11/22	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	02/10/22	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	21/09/22	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-3.68%	45.67M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+49.05%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research

Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Initiator Pharma Seeks IPO

Latest news about Initiator Pharma A/S

Chart Initiator Pharma A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research